FDA clears way for generic versions of Lamictal
WASHINGTON, March 2 |
WASHINGTON, March 2 (Reuters) - The U.S. Food and Drug Administration on Friday said GlaxoSmithKline Plc's (GSK.L) (GSK.N) seizure drug Lamictal was not withdrawn from sale for safety or effectiveness reasons.
The FDA said the ruling paves the way for the agency to approve generic versions of the drug, also known as lamotrigine.
- Tweet this
- Link this
- Share this
- Digg this
- Reprints
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
Follow Reuters